

1 **COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank**
2 **participants**

3 S J Woolford* ^a, S D'Angelo* ^a, E M Curtis ^a, C M Parsons ^a, K A Ward ^a, E M Dennison ^a, H P Patel ^{a, b, c,}
4 ^d, C Cooper ^{+ a, d, e}, N C Harvey ^{+ a, d}

5

6 * SJW and SD are joint first author; ⁺ CC and NCH are joint senior author

7

8 ^a MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

9 ^b Medicine for Older People, University Hospital Southampton, Southampton, UK

10 ^c Academic Geriatric Medicine, University of Southampton, Southampton, UK

11 ^d NIHR Southampton Biomedical Research Centre, University of Southampton and University
12 Hospital Southampton NHS Foundation Trust, Southampton, UK

13 ^e NIHR Biomedical Research Centre, University of Oxford, Oxford, UK

14

15 **Corresponding author**

16 Prof Nicholas Harvey

17 Email address: nch@mrc.soton.ac.uk

18 Full postal address: MRC Lifecourse Epidemiology Unit, Tremona Road, Southampton, SO16 6YD, UK

19

20

21

22 **Abstract**

23 *Background*

24 Frailty and multimorbidity have been suggested as risk factors for severe COVID-19 disease.

25

26 *Aims*

27 We investigated whether frailty and multimorbidity were associated with risk of hospitalisation with
28 COVID-19 in the UK Biobank.

29

30 *Methods*

31 502,640 participants aged 40-69 years at baseline (54-79 years at COVID-19 testing) were recruited
32 across UK 2006-10. A modified assessment of frailty using Fried's classification was generated from
33 baseline data. COVID-19 test results (England) were available 16/03/2020-01/06/2020, mostly taken
34 in hospital settings. Logistic regression was used to discern associations between frailty,
35 multimorbidity and COVID-19 diagnoses, adjusting for sex, age, BMI, ethnicity, education, smoking
36 and number of comorbidity groupings, comparing COVID-19 positive, COVID-19 negative and non-
37 tested groups.

38

39 *Results*

40 4,510 participants were tested for COVID-19 (positive=1,326, negative=3,184). 497,996 participants
41 were not tested. Compared to the non-tested group, after adjustment, COVID-19 positive
42 participants were more likely to be frail (OR=1.3 [95% CI=1.1, 1.7]), report slow walking speed
43 (OR=1.3 [1.1, 1.6]), report two or more falls in the past year (OR=1.3 [1.0, 1.5]) and be multimorbid
44 (≥ 4 comorbidity groupings vs 0-1: OR=1.9 [1.5, 2.3]). However, similar strength of associations were

45 apparent when comparing COVID-19 negative and non-tested groups. Furthermore, frailty and
46 multimorbidity were not associated with COVID-19 diagnoses, when comparing COVID-19 positive
47 and COVID-19 negative participants.

48

49 *Discussion and conclusions*

50 Frailty and multimorbidity do not appear to aid risk stratification, in terms of a positive versus
51 negative results of COVID-19 testing. Investigation of the prognostic value of these markers for
52 adverse clinical sequelae following COVID-19 disease is urgently needed.

53

54 **Keywords**

55 COVID-19; frailty; musculoskeletal; UK Biobank; osteoporosis; epidemiology

56

57

58

59

60

61

62

63

64

65

66 **Declarations**

67 *Funding (information that explains whether and by whom the research was supported)*

68 This work was supported by the UK Medical Research Council, Wellcome Trust, National Institute for
69 Health Research, Versus Arthritis, Royal Osteoporosis Society Osteoporosis and Bone Research
70 Academy, International Osteoporosis Foundation, NIHR Southampton Biomedical Research Centre,
71 University of Southampton, University Hospital Southampton NHS Foundation Trust and NIHR
72 Oxford Biomedical Research Centre. EMC is supported by the Wellcome Trust (201268/Z/16/Z).

73

74 *Conflicts of interest/Competing interests (include appropriate disclosures)*

75 The authors report no conflicting or competing interests in relation to this work.

76

77 *Ethics approval (include appropriate approvals or waivers)*

78 This study had ethics approval as part of overall UK Biobank ethics approval (NHS National Research
79 Ethics Service 16/NW/0274). We undertook the study under UK Biobank Access Application 3593.

80

81 *Consent to participate (include appropriate statements)*

82 All UK Biobank participants gave written informed consent for data collection, analysis, and linkage.

83

84 *Consent for publication (include appropriate statements)*

85 All UK Biobank participants gave written informed consent for data collection, analysis, and linkage.

86

87 *Availability of data and material (data transparency)*

88 Approval for access to data used in this study is via UK Biobank (approved Access Application 3593).

89

90 *Code availability (software application or custom code)*

91 All analyses were performed with Stata v 15.1 (StataCorp, College Station, Texas, USA). No custom

92 code was used.

93

94 *Authors' contributions (optional: please review the submission guidelines from the journal whether*

95 *statements are mandatory)*

96 SJW and SD performed the analysis and created the original manuscript, with senior supervision

97 from NCH. CMP gave expert statistical advice. EMC, KW, EMD, HP and CC contributed

98 epidemiological and clinical musculoskeletal/gerontological expertise. All authors reviewed and

99 approved the final manuscript, providing comments and amendments.

100

101

102

103

104

105

106

107

108 **Background**

109 The first case of 2019 Novel Coronavirus (COVID-19) disease (caused by the Severe Acute Respiratory
110 Syndrome Coronavirus 2 [SARS-CoV-2]) was reported in Wuhan, China in December 2019 [1]. Since
111 then, the number of global cases have increased rapidly, with the WHO declaring COVID-19 a
112 pandemic in March 2020 [2]. At the time of manuscript preparation, more than 5 million cases have
113 been confirmed across 213 countries and territories, with more than 300,000 associated deaths [3].

114 The identification of risk factors for contracting COVID-19 is crucial, in order to inform public health
115 policy and facilitate the appropriate distribution of healthcare resources. Preliminary data from Asia,
116 Europe and the United States suggest that the majority of individuals with COVID-19 are aged >50
117 years, with most deaths occurring in those aged >60 years [4-7]. Multimorbidity has also been
118 associated with COVID-19 disease, the need for ventilatory support and higher rates of mortality [4-
119 7]. As a result, COVID-19 patients have frequently been described within the academic discourse as
120 “frail”, with this term being used in its more colloquial sense [8-10]. Furthermore, clinical
121 management guidelines, such as those produced by the UK National Institute for Health and Care
122 Excellence (NICE), typically recommend the assessment of frailty as the initial step when triaging
123 suspected COVID-19 patients [11]. However, the clinical syndrome of frailty has yet to be formally
124 examined in relation to COVID-19 disease, beyond single case reports [12].

125 Therefore, we aimed to examine the associations between COVID-19 diagnoses, frailty and
126 multimorbidity within the UK Biobank, a large prospective community cohort of over half a million
127 UK residents.

128

129 **Methods**

130 *Study population*

131 This study was a prospective community-based cohort analysis of UK Biobank participants. Between
132 2006 and 2010 potential participants were invited for recruitment, with inclusion criteria being
133 registered with a general practitioner, living within reasonable travelling distance of an assessment
134 centre and being aged 40-69 years. 502,640 participants were recruited across 22 assessment
135 centres in England, Scotland and Wales, with a response rate of 5%.

136

137 *Baseline characteristics*

138 Information on lifestyle, social history and medical history was collected using a series of computer-
139 based touchscreen questionnaires, followed by face-to-face interviews with trained research staff.
140 Recorded data included sex, age, ethnicity, level of educational attainment, alcohol consumption
141 (never or special occasions only; one to three times per month; one to four times per week; or daily
142 or almost daily), smoking status (never smoked; ex-smoker; or current smoker) and number of falls
143 in the past year (no falls; only one fall; or more than one fall). Height and weight were also measured
144 by trained research staff using a standardised technique, and BMI was subsequently calculated
145 (kg/m^2).

146

147 *Assessment of frailty*

148 We calculated frailty using a modified version of five frailty phenotype indicators originally reported
149 by Fried and colleagues [13], and later adapted for use in the UK Biobank data set [14]. Table 1
150 outlines the criteria for the frailty indicators used, compared to Fried and colleagues original criteria.
151 The criteria for the low physical activity frailty indicator was further adapted for use in this study,
152 based on a comparable exercise metric within the data set available to us. Grip strength was
153 measured using a Jamar J00105 hydraulic hand dynamometer, with both right and left hands being
154 assessed and the lower result used in the analysis. The other frailty indicators were assessed via self-

155 reported touchscreen questionnaire answers. The associations with multiple falls in the past year
156 with COVID-19 diagnoses was also examined, due to the associations of frequent falls with frailty
157 and the frequency of which a fall is the first presentation of the frailty syndrome to healthcare
158 providers [15,16].

159 As per Fried and colleagues, participants were classified as not frail (0 frailty indicators), pre-frail (1-2
160 frailty indicators) or frail (≥ 3 more frailty indicators). Frailty status was not calculated for participants
161 with missing data for three or more frailty indicators, as per Fried and colleague's methodology.

162

163 *Assessment of multimorbidity*

164 Participants reported doctor-diagnosed chronic health conditions during face-to-face interviews at
165 study recruitment, apart from cancer, which was reported during touchscreen questionnaires. To
166 avoid repeated counting of closely related or clinically similar chronic health conditions,
167 comorbidities have been categorised according to 43 comorbidity groupings, originally established
168 for a large epidemiological study in Scotland [17], and subsequently amended for use in the UK
169 Biobank [18]. Supplementary Table 1 shows the full list of comorbidity groupings and the
170 corresponding health conditions. Number of comorbidity groupings were then summed, and
171 categorised (0-1; 2; 3 or ≥ 4 comorbidity groupings).

172

173 *COVID-19 testing*

174 COVID-19 diagnoses were sourced via available COVID-19 test results within the UK Biobank data set
175 at the time of manuscript preparation (from 16th March 2020 to 1st June 2020), sourced from Public
176 Health England [19]. The vast majority of these COVID-19 tests were via a combined nasal and throat
177 swab. In intensive care settings, lower respiratory secretion samples were also subject to COVID-19

178 testing. Samples were transported in a medium suitable for viruses (typically a balanced salt
179 solution), and PCR-based testing was performed.

180 The time period from which COVID-19 testing data were available for analysis from the UK Biobank
181 was during the peak of the UK COVID-19 outbreak, when the overwhelming majority of COVID-19
182 testing took place in hospital settings. Therefore, it can be assumed that all those who were tested
183 for COVID-19 presented with symptoms, due to COVID-19 or otherwise, severe enough to warrant
184 hospital admission. The background population group represent those not tested for COVID-19,
185 including those who had did not have COVID-19, as well as undiagnosed COVID-19 cases who were
186 asymptomatic or only had mild symptoms. Current prevalence estimates of undiagnosed COVID-19
187 cases within the UK community population are approximately 0.3% [20].

188

189 *Statistical analysis*

190 Participants were divided into three groups for comparison: 1) participants who tested positive for
191 COVID-19 (COVID-19 +ve group), 2) participants who tested negative for COVID-19 (COVID-19 -ve
192 group), and 3) participants who had not been tested for COVID-19 (background population group).

193 Baseline characteristics of these three groups were analysed by reporting mean (standard deviation,
194 SD) or median (interquartile range, IQR) as appropriate for continuous variables, and number
195 (percentages) for categorical variables. Differences between groups were tested with unpaired t-
196 tests, Mann-Whitney U tests or Pearson Chi-square tests, as appropriate.

197 Logistic regression was used to explore the associations between COVID-19 +ve vs COVID-19 -ve
198 groups and frailty status, frailty indicators, number of falls in the past year and number of
199 comorbidity groupings, with groups being stratified for age (<60 or ≥60 years at baseline). Covariates
200 considered included sex, age, BMI, ethnicity, educational attainment, smoking status and number of

201 comorbidity groupings (where comorbidity was not the exposure). Similar analyses for COVID-19 +ve
202 and COVID-19 -ve groups vs the background population group were also performed.

203 All analyses were performed with Stata v 15.1 (StataCorp, College Station, Texas, USA). All UK
204 Biobank participants gave written informed consent for data collection, analysis, and linkage at study
205 recruitment. This study had ethics approval as part of overall UK Biobank ethics approval (NHS
206 National Research Ethics Service 16/NW/0274). We undertook the study under UK Biobank Access
207 Application 3593.

208

209 **Results**

210 *Study population*

211 A total of 4,510 UK Biobank participants were tested for COVID-19. Of these, 1,326 tested positive
212 and 3,184 tested negative. 497,996 participants were not tested. 1,769 participants had missing data
213 for three or more frailty indicators, and were excluded from any analyses requiring these data.

214

215 *Baseline characteristics*

216 Table 2 shows the baseline characteristics of the three comparative groups. The median age ranged
217 from 58-60 years by group, consistent with the recruitment criteria of ages 40-69 years. Median age
218 at the time of COVID-19 testing was 70 and 71 years, for those who tested positive and negative
219 respectively. The COVID-19 +ve group were more likely to be male, of greater BMI, of non-white
220 ethnicity and lower educational attainment, and less likely to consume alcohol and to have never
221 smoked, when compared with the background population group. They were also more likely to be
222 frail, exhibit a number of frailty indicators (weight loss, exhaustion, slow walking speed and
223 weakness of grip), to report two or more falls in the past year and to report a higher number of
224 comorbidity groupings, when compared with the background population group. However,

225 comparison of COVID-19 -ve group with the background population group yielded a similar pattern
226 of results, apart from being less likely to be male.

227 When comparing COVID-19 +ve and -ve groups, COVID-19 +ve participants were more likely to be
228 male, of greater BMI, of non-white ethnicity, greater BMI, of lower educational attainment and
229 consume less alcohol than COVID-19 -ve participants. However, the two groups did not differ in
230 terms of frailty status, frailty indicators, falls in the past year or number of comorbidity groupings.

231

232 *Associations between frailty, falls, multimorbidity and COVID-19 diagnoses*

233 Table 3 documents the associations between potential COVID-19 risk factors in the COVID-19 +ve
234 group vs the COVID-19 -ve groups, also stratified by age (<60 or ≥60 years at baseline, corresponding
235 to <70-74 and ≥70-74 years at COVID-19 testing). After adjustment for sex, age, BMI, ethnicity,
236 educational attainment, smoking status and number of comorbidity groupings there were no
237 associations between frailty, indicators of frailty, falls in the past year or number of comorbidity
238 groupings and testing positive for COVID-19. Age stratification revealed no additional associations at
239 older or younger ages. However, odds ratios for frailty indicators and multimorbidity were, in
240 general, more likely to be greater than unity in the older age group, compared with those for the
241 younger age group.

242 Logistic regression models for potential COVID-19 risk factors in COVID-19 +ve or -ve groups vs the
243 background population group are presented in Table 4. After adjustment, both the COVID-19 +ve
244 and -ve groups displayed greater odds of frailty, a number of frailty indicators and higher number of
245 comorbidities, when compared with the background population group. The strength of associations
246 were comparable in both groups.

247

248 **Discussion**

249 To our knowledge and at the time of manuscript preparation, this is the first study to investigate
250 associations between the frailty syndrome and COVID-19 diagnoses. Importantly, we have
251 demonstrated that such classification may not aid risk stratification in terms of COVID-19
252 vulnerability, contrasting with other attributes, such as male sex, non-white ethnicity and greater
253 BMI. Our findings also highlight that many characteristics of those hospitalised with COVID-19
254 disease are shared by those hospitalised for other reasons. However, it remains possible that factors
255 such as frailty and multimorbidity may influence adverse outcomes following infection with SARS-
256 CoV-2.

257 There are several limitations to this study. Firstly, the characteristics of participants used to calculate
258 frailty and multimorbidity status for this study were recorded at recruitment into the UK Biobank,
259 between 2006 and 2010. As such, participants may have accumulated markers of frailty or additional
260 comorbidities after initial data collection, and so may be misclassified in the present analysis. The
261 population studied was also relatively young, in terms of the wider frail population, when age was
262 recorded at baseline [21]. However, given that such attributes develop over time, participants were
263 substantially older (50-84 years) at time of COVID-19 testing, and we additionally analysed by age
264 strata. Secondly, the COVID-19 test results used in this study, which are only from England, are also
265 subject to limitations. Given that the majority of tests were undertaken in hospital, we cannot
266 comment on the associations for asymptomatic or low severity COVID-19 cases within the
267 community. Furthermore, the sensitivity of PCR-based testing has been reported as lower than chest
268 CT imaging, potentially due to low viral load at the time of testing or inappropriate testing technique
269 [22,23]. Therefore, the number of COVID-19 positive diagnoses within our sample may be
270 underrepresented. Thirdly, at the time of manuscript preparation, mortality data for those tested for
271 COVID-19 are not yet available within the UK Biobank resource. As such, we cannot comment on the
272 associations for frailty and multimorbidity with COVID-19-associated mortality. Fourthly, records of
273 clinical events occurring during hospital admissions are not available within the UK Biobank data set.
274 Because of this, we also cannot comment on associations with adverse COVID-19 outcomes, such as

275 non-invasive ventilation, intensive care admission or length of hospital stay. Finally, owing to the
276 observational nature of this study causality cannot be inferred from our results.

277 Frailty is common, with global prevalence in those aged >85 years estimated to be 26% [21]. Frailty is
278 characterised by a physiological vulnerability to stressor events, such as acute illnesses or hospital
279 admissions, after which the individual fails to return to their previous baseline of health [24].
280 Ultimately, an individual living with frailty is predisposed to a significantly increased risk of hospital
281 admission and higher rates of mortality [25]. Multimorbidity, defined as the presence of two or more
282 chronic health conditions, is also common, with UK population estimates ranging from 15 to 30%
283 [26]. Whilst multimorbidity is often present in those who are frail [27], it is also associated with
284 greater risk of unplanned hospital admissions and increased mortality, independent of frailty
285 [28,29]. Our results are in keeping with this existing literature regarding frailty and multimorbidity,
286 with these populations being more susceptible to physiological insults such as COVID-19, and more
287 likely to experience a severity of disease which requires hospitalisation. Importantly, our results
288 suggest that people living with frailty and multimorbidity are no more likely to require a hospital
289 admission due to COVID-19 compared to other conditions resulting in similar disease severity.
290 Therefore, the reported high rates of COVID-19 diagnoses and mortality in those with multiple
291 health conditions and those who are characterised as frail [4-7] are likely due to the highly
292 contagious nature of COVID-19, and potential susceptibility to severe sequelae, rather than a specific
293 propensity to contracting the disease.

294 The routine assessment of frailty during the COVID-19 pandemic has been frequently advocated, in
295 order to facilitate appropriate management and resource allocation [8,30,10]. Additionally, in the
296 UK, current NICE guidelines recommend the assessment of frailty as the initial step when assessing
297 suspected COVID-19 patients on admission to hospital [11]. This assessment can then be used to
298 inform decisions for escalation to intensive care environments where ventilatory support can be
299 provided, in the case of patient deterioration. It has also been recommended that people living with

300 multimorbidity or who are likely to be frail should minimise their exposure to the general population
301 in order to reduce their risk of contracting COVID-19 [31]. To this end, Public Health England
302 implemented a “shielding” strategy on 21st March 2020, with particularly at risk patient groups being
303 contacted based on underlying health conditions, and instructed to self-isolate until further notice
304 [32]. We have not demonstrated any differences in frailty between those testing positive compared
305 with those testing negative for COVID-19 (i.e. when comparing two groups presenting with disease,
306 COVID-19 or otherwise, serious enough to warrant hospital admission). However, our findings do not
307 allow comment on the predictive value of frailty for subsequent outcomes of COVID-19. They do,
308 however, demonstrate that such individuals are generally at high risk of hospitalisation and requiring
309 testing for COVID-19, and therefore risk minimisation for older frail or multimorbid individuals
310 remains highly appropriate.

311 Finally, it is important not to view older age as synonymous with frailty when used as a potential risk
312 factor for COVID-19. Whilst the majority of people living with frailty are older persons [21], a notable
313 proportion of frail individuals are middle-aged [14]. The age range at baseline within our sample was
314 40-69 years, but it is important to note that this was during 2006-2010, and the age range at COVID-
315 19 diagnosis was substantially older (50-84 years). Furthermore, although not statistically significant,
316 the pattern of associations stratified by <60 or ≥60 years at baseline was consistent with the notion
317 that frailty markers (here potentially assessed early in their development) might be more relevant in
318 those contracting the COVID-19 at older ages.

319

320 **Conclusions**

321 This is the first study to investigate associations between the frailty syndrome, multimorbidity and
322 COVID-19 diagnoses within a large and well characterised prospective observational cohort. We
323 have shown that no differences were evident for frailty status or number of morbidities when
324 comparing those who tested positive for COVID-19 and those who tested negative, suggesting that

325 the associations compared to the background population represent propensity to disease requiring
326 hospital admission, rather than COVID-19 positivity per se. Studies are now urgently needed to
327 examine the prognostic value of frailty and multimorbidity for adverse clinical sequelae following
328 SARS-CoV-2 infection.

329

330 **Acknowledgments**

331 This work was supported by the UK Medical Research Council, Wellcome Trust, National Institute for
332 Health Research, Versus Arthritis, Royal Osteoporosis Society Osteoporosis and Bone Research
333 Academy, International Osteoporosis Foundation, NIHR Southampton Biomedical Research Centre,
334 University of Southampton, University Hospital Southampton NHS Foundation Trust and NIHR
335 Oxford Biomedical Research Centre. EMC is supported by the Wellcome Trust (201268/Z/16/Z). SJW
336 and SD are joint first author. CC and NCH are joint senior author.

337

338

339

340

341

342

343

344

345

346

347

348

349

350 **References**

351 1. Du Toit A (2020) Outbreak of a novel coronavirus. *Nature Reviews Microbiology* 18 (3):123-123

352 2. Organisation WH (2020) WHO Director-General's opening remarks at the media briefing on

353 COVID-19 - 11 March 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s->

354 [opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020). Accessed 25/05/20

355 3. Organisation WH (2020) Coronavirus disease 2019 (COVID-19): situation report, 125.

356 4. Boddington NL, Charlett A, Elgohari S, Walker JL, McDonald H, Byers C, Coughlan L, Vilaplana TG,

357 Whillock R, Sinnathamby M (2020) COVID-19 in Great Britain: epidemiological and clinical

358 characteristics of the first few hundred (FF100) cases: a descriptive case series and case control

359 analysis. medRxiv

360 5. Surveillances V (2020) The epidemiological characteristics of an outbreak of 2019 novel

361 coronavirus diseases (COVID-19)—China, 2020. *China CDC Weekly* 2 (8):113-122

362 6. Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in

363 relation to COVID-19 in Italy. *Jama*

364 7. COVID C, Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, Ritchey M (2020)

365 Preliminary estimates of the prevalence of selected underlying health conditions among patients

366 with coronavirus disease 2019—United States, February 12–March 28, 2020. *Morbidity and*

367 *Mortality Weekly Report* 69 (13):382

- 368 8. Abbatecola A, Antonelli-Incalzi R (2020) COVID-19 Spiraling of Frailty in Older Italian Patients. The
369 Journal of Nutrition, Health & Aging 1
- 370 9. Polidori MC, Maggi S, Mattace-Raso F, Pilotto A (2020) The unavoidable costs of frailty: a geriatric
371 perspective in the time of COVID-19. Geriatric Care 6 (1)
- 372 10. Sinclair A, Abdelhafiz A (2020) Age, frailty and diabetes—triple jeopardy for vulnerability to
373 COVID-19 infection. EClinicalMedicine
- 374 11. Excellence NifHaC (2020) COVID-19 rapid guideline: critical care in adults: NICE guideline
375 [NG159]. <https://www.nice.org.uk/guidance/ng159>. Accessed 25/05/20
- 376 12. Tay HS, Harwood R (2020) Atypical presentation of COVID-19 in a frail older person. Age and
377 ageing
- 378 13. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ,
379 Burke G (2001) Frailty in older adults: evidence for a phenotype. The Journals of Gerontology Series
380 A: Biological Sciences and Medical Sciences 56 (3):M146-M157
- 381 14. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS (2018) Frailty and pre-frailty in
382 middle-aged and older adults and its association with multimorbidity and mortality: a prospective
383 analysis of 493 737 UK Biobank participants. The Lancet Public Health 3 (7):e323-e332
- 384 15. Ensrud KE, Ewing SK, Cawthon PM, Fink HA, Taylor BC, Cauley JA, Dam TT, Marshall LM, Orwoll
385 ES, Cummings SR (2009) A comparison of frailty indexes for the prediction of falls, disability,
386 fractures, and mortality in older men. Journal of the American Geriatrics Society 57 (3):492-498
- 387 16. Kojima G (2015) Frailty as a predictor of future falls among community-dwelling older people: a
388 systematic review and meta-analysis. Journal of the American Medical Directors Association 16
389 (12):1027-1033

- 390 17. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of
391 multimorbidity and implications for health care, research, and medical education: a cross-sectional
392 study. *The Lancet* 380 (9836):37-43
- 393 18. Nicholl BI, Mackay D, Cullen B, Martin DJ, Ul-Haq Z, Mair FS, Evans J, McIntosh AM, Gallagher J,
394 Roberts B (2014) Chronic multisite pain in major depression and bipolar disorder: cross-sectional
395 study of 149,611 participants in UK Biobank. *BMC psychiatry* 14 (1):350
- 396 19. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, O'Connell AM (2020) Dynamic
397 linkage of COVID-19 test results between Public Health England's Second Generation Surveillance
398 System and UK Biobank. *Microbial Genomics*. doi:doi: 10.1099/mgen.0.000397
- 399 20. Statistics OfN (2020) Coronavirus (COVID-19) Infection Survey pilot: England, 21 May 2020.
400 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseas](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveysurvey/28may2020)
401 [es/bulletins/coronaviruscovid19infectionsurveysurvey/28may2020](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveysurvey/28may2020). Accessed 25/05/20
- 402 21. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC (2012) Prevalence of frailty in community-
403 dwelling older persons: a systematic review. *Journal of the American Geriatrics Society* 60 (8):1487-
404 1492. doi:10.1111/j.1532-5415.2012.04054.x
- 405 22. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W (2020) Sensitivity of chest CT for COVID-19:
406 comparison to RT-PCR. *Radiology*:200432
- 407 23. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H (2020) Diagnosis of the
408 Coronavirus disease (COVID-19): rRT-PCR or CT? *European journal of radiology*:108961
- 409 24. Woolford S, Sohan O, Dennison E, Cooper C, Patel H (2020) Approaches to the diagnosis and
410 prevention of frailty. *Aging clinical and experimental research*

- 411 25. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. *The lancet* 381
412 (9868):752-762
- 413 26. Aiden H (2018) Multimorbidity. *Understanding the Challenge*
- 414 27. Vetrano DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wirnsberger R, Lopez
415 Samaniego L, Rodríguez-Mañas L, Bernabei R, Onder G (2019) Frailty and multimorbidity: a
416 systematic review and meta-analysis. *The Journals of Gerontology: Series A* 74 (5):659-666
- 417 28. Excellence NfHaC (2016) Multimorbidity: clinical assessment and management: NICE guideline
418 [NG56]. <https://www.nice.org.uk/guidance/ng56>. Accessed 26/05/20
- 419 29. Nunes BP, Flores TR, Mielke GI, Thume E, Facchini LA (2016) Multimorbidity and mortality in
420 older adults: a systematic review and meta-analysis. *Archives of gerontology and geriatrics* 67:130-
421 138
- 422 30. Boreskie KF, Boreskie PE, Melady D (2020) Age is just a number—and so is frailty: Strategies to
423 inform resource allocation during the COVID-19 pandemic. *Canadian Journal of Emergency*
424 *Medicine*:1-3
- 425 31. Landi F, Barillaro C, Bellieni A, Brandi V, Carfi A, D'Angelo M, Fusco D, Landi G, Monaco RL,
426 Martone A (2020) The new challenge of geriatrics: saving frail older people from the Sars-COV-2
427 pandemic infection. *The Journal of Nutrition, Health & Aging*:1
- 428 32. England PH (2020) Guidance on shielding and protecting people who are clinically extremely
429 vulnerable from COVID-19. [https://www.gov.uk/government/publications/guidance-on-shielding-
430 and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-
431 extremely-vulnerable-persons-from-covid-19](https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19). Accessed 26/05/20
- 432

Table 1

Frailty indicators originally adapted for use in the UK Biobank by Hanlon and colleagues, based on Fried and colleagues original frailty phenotype.

	Cardiovascular Health Study frailty indicators (Fried and colleagues) [13]	Adapted UK Biobank frailty indicators (Hanlon and colleagues) [14]
Weight loss	Self-reported: "In the last year, have you lost more than 10 pounds unintentionally?" <ul style="list-style-type: none"> • Yes=1, no=0 	Self-reported: "Compared with one year ago, has your weight changed?" <ul style="list-style-type: none"> • Yes, lost weight=1, other=0
Exhaustion	Self-reported: "How often in the last week (a) did you feel that everything was an effort, or (b) could you not get going?" <ul style="list-style-type: none"> • Moderate amount of the time [3–4 days] or most of the time=1, other=0 	Self-reported: "Over the past two weeks, how often have you felt tired or had little energy?" <ul style="list-style-type: none"> • More than half the days or nearly every day=1, other=0
Low physical activity	Self-reported: Minnesota Leisure Time Activity Questionnaire and Kcal of activity per week subsequently estimated. <ul style="list-style-type: none"> • Lowest 20% of cohort=1, other=0 	Self-reported: "In a typical week, on how many days did you do 10 minutes or more of moderate physical activities like carrying light loads, cycling at normal pace? (do not include walking)" * <ul style="list-style-type: none"> • 0-1 day/week=1, other=0
Slow walking speed	Measured time to walk 15 feet. <ul style="list-style-type: none"> • Lowest 20% of cohort=1, other=0 	Self-reported: "How would you describe your usual walking pace?" <ul style="list-style-type: none"> • Slow=1, other=0
Grip strength	Measured grip strength, adjusted for sex and body-mass index. <ul style="list-style-type: none"> • Lowest 20% of cohort=1, other=0 	Measured grip strength. <ul style="list-style-type: none"> • Sex and body-mass index adjusted cut-offs taken from Fried and colleagues.

* Criteria not from Hanlon and colleagues, and based on comparable data available for use for the purposes of this study.

Table 2

Characteristics of background population, COVID-19 +ve and COVID-19 -ve groups.

	Background population n=497,996	COVID-19 +ve n=1,326	COVID-19 -ve n=3,184	COVID-19 +ve vs background population	COVID-19 -ve vs background population	COVID-19 +ve vs COVID-19 -ve
Sex (male)	226,921 (45.6%)	696 (52.5%)	1,505 (47.3%)	<0.001	0.06	0.001
Age at baseline, years	58.0 (50.0, 63.0)	58.0 (47.0, 65.0)	60.0 (50.0, 65.0)	0.24	<0.001	0.02
BMI, (kg/m ²)	27.4 (4.8)	28.9 (5.5)	28.2 (5.5)	<0.001	<0.001	<0.001
Ethnicity (white)	468,629 (94.3%)	1,141 (86.2%)	2,927 (92.1%)	<0.001	<0.001	<0.001
Educational attainment						
College or university degree	159,914 (32.8%)	320 (24.9%)	930 (30.1%)	<0.001	<0.001	0.001
A level equivalent	161,195 (33.0%)	463 (36.0%)	989 (32.0%)			
GCSE equivalent or less	166,883 (34.2%)	504 (39.2%)	1,176 (38.0%)			
Alcohol consumption						
At least 3 times per week	216,969 (43.6%)	445 (33.6%)	1,295 (40.7%)	<0.001	0.001	<0.001
Smoking status						
Never smoked	271,353 (54.8%)	643 (49.0%)	1,526 (48.3%)	<0.001	<0.001	0.03
Ex-smoker	171,339 (34.6%)	525 (40.0%)	1,194 (37.8%)			
Current smoker	52,392 (10.6%)	145 (11.0%)	441 (14.0%)			
Frailty indicators						
Weight loss	75,053 (15.4%)	235 (18.2%)	545 (17.5%)	0.005	0.001	0.61
Exhaustion	61,417 (12.8%)	231 (18.3%)	537 (17.5%)	<0.001	<0.001	0.55
Low physical activity	98,518 (20.9%)	261 (21.6%)	660 (22.3%)	0.56	0.07	0.64
Slow walking speed	40,229 (8.2%)	203 (15.6%)	478 (15.3%)	<0.001	<0.001	0.78
Weakness of grip	141,596 (28.6%)	447 (34.0%)	1,155 (36.5%)	<0.001	<0.001	0.12
Frailty status						
Not frail	214,084 (43.1%)	463 (35.2%)	1,134 (35.8%)	<0.001	<0.001	0.73
Pre-frail	254,778 (51.3%)	727 (55.2%)	1,712 (54.0%)			
Frail	27,389 (5.5%)	127 (9.6%)	323 (10.2%)			
Falls in past year						
≥2	32,704 (6.6%)	132 (10.1%)	302 (9.5%)	<0.001	<0.001	0.58
Number of comorbidity groupings						
0-1	339,159 (68.1%)	754 (56.9%)	1,780 (55.9%)	<0.001	<0.001	0.25
2	92,691 (18.6%)	281 (21.2%)	684 (21.5%)			
3	41,401 (8.3%)	168 (12.7%)	367 (11.5%)			
≥4	24,745 (5.0%)	123 (9.3%)	353 (11.1%)			

Data are mean (SD), median (IQR), number (%) and p value. Bold text denotes p values <0.05.

Table 3

Associations for COVID-19 risk factors in COVID-19 +ve vs COVID-19 -ve groups.

	Unadjusted			Adjusted ¹		
	All	<60 years at baseline	≥60 years at baseline	All	<60 years at baseline	≥60 years at baseline
Frailty status						
Not frail	Reference	Reference	Reference	Reference	Reference	Reference
Pre-frail	1.1 (0.9, 1.3)	1.0 (0.8, 1.2)	1.1 (0.9, 1.4)	1.0 (0.8, 1.2)	0.9 (0.7, 1.1)	1.1 (0.9, 1.4)
Frail	1.0 (0.8, 1.3)	0.8 (0.6, 1.2)	1.2 (0.8, 1.6)	0.9 (0.6, 1.2)	0.7 (0.5, 1.0)	1.0 (0.7, 1.5)
Frailty indicators						
Weight loss	1.1 (0.9, 1.3)	1.0 (0.8, 1.3)	1.1 (0.9, 1.4)	1.1 (0.9, 1.3)	1.0 (0.8, 1.3)	1.1 (0.8, 1.4)
Exhaustion	1.0 (0.8, 1.2)	1.0 (0.8, 1.3)	1.1 (0.8, 1.4)	1.0 (0.8, 1.2)	1.0 (0.8, 1.3)	1.0 (0.7, 1.3)
Low physical activity	1.0 (0.8, 1.2)	0.8 (0.6, 1.0)	1.2 (0.9, 1.5)	0.9 (0.8, 1.1)	0.8 (0.6, 1.0)	1.2 (0.9, 1.5)
Slow walking speed	1.1 (0.9, 1.4)	0.8 (0.6, 1.1)	1.2 (1.0, 1.6)	1.0 (0.8, 1.2)	0.7 (0.5, 1.0)	1.2 (0.9, 1.5)
Weakness of grip	0.9 (0.8, 1.1)	0.9 (0.8, 1.2)	0.9 (0.7, 1.1)	0.9 (0.7, 1.0)	0.9 (0.7, 1.1)	0.9 (0.7, 1.1)
Falls in past year						
0-1	Reference	Reference	Reference	Reference	Reference	Reference
≥2	1.1 (0.9, 1.4)	0.9 (0.8, 1.1)	1.0 (0.9, 1.1)	1.1 (0.9, 1.5)	0.9 (0.8, 1.1)	1.0 (0.9, 1.2)
Number of comorbidity groupings						
0-1	Reference	Reference	Reference	Reference	Reference	Reference
2	1.0 (0.9, 1.2)	1.0 (0.8, 1.2)	1.1 (0.8, 1.3)	1.0 (0.8, 1.2)	1.0 (0.7, 1.2)	1.0 (0.8, 1.3)
3	1.3 (1.0, 1.6)	0.9 (0.7, 1.3)	1.3 (0.9, 1.7)	1.2 (0.9, 1.5)	0.8 (0.6, 1.1)	1.2 (0.9, 1.6)
≥4	0.9 (0.7, 1.1)	0.8 (0.6, 1.2)	0.9 (0.7, 1.2)	0.8 (0.6, 1.0)	0.7 (0.5, 1.1)	0.8 (0.6, 1.1)

Data are odds ratio (95%CI).

¹ Adjusted for sex, age, BMI, ethnicity, educational attainment, smoking status and number of comorbidity groupings (except when analysing this association).

Table 4

Associations for COVID-19 risk factors in COVID-19 +ve and COVID-19 -ve groups vs background population group.

	Unadjusted		Adjusted ¹	
	COVID-19 +ve vs background population	COVID-19 -ve vs background population	COVID-19 +ve vs background population	COVID-19 -ve vs background population
Frailty status				
Not frail	Reference	Reference	Reference	Reference
Pre-frail	1.3 (1.2, 1.5)	1.3 (1.2, 1.4)	1.1 (0.9, 1.3)	1.1 (1.0, 1.2)
Frail	2.1 (1.8, 2.6)	2.2 (2.0, 2.5)	1.3 (1.1, 1.7)	1.6 (1.4, 1.8)
Frailty indicators				
Weight loss	1.2 (1.1, 1.4)	1.2 (1.1, 1.3)	1.1 (1.0, 1.3)	1.1 (1.0, 1.2)
Exhaustion	1.5 (1.3, 1.8)	1.5 (1.3, 1.6)	1.2 (1.0, 1.4)	1.2 (1.1, 1.3)
Low physical activity	1.0 (0.9, 1.2)	1.1 (1.0, 1.2)	0.9 (0.8, 1.1)	1.0 (0.9, 1.1)
Slow walking speed	2.1 (1.8, 2.4)	2.0 (1.8, 2.2)	1.3 (1.1, 1.6)	1.5 (1.3, 1.6)
Weakness of grip	1.3 (1.2, 1.4)	1.4 (1.3, 1.5)	1.1 (0.9, 1.2)	1.2 (1.1, 1.3)
Falls in past year				
0-1	Reference	Reference	Reference	Reference
≥2	1.2 (1.1, 1.3)	1.5 (1.3, 1.7)	1.3 (1.0, 1.5)	1.2 (1.0, 1.3)
Number of comorbidity groupings				
0-1	Reference	Reference	Reference	Reference
2	1.4 (1.2, 1.6)	1.4 (1.3, 1.5)	1.3 (1.1, 1.5)	1.3 (1.2, 1.4)
3	1.8 (1.5, 2.2)	1.7 (1.5, 1.9)	1.6 (1.3, 1.9)	1.6 (1.4, 1.7)
≥4	2.2 (1.8, 2.7)	2.7 (2.4, 3.0)	1.9 (1.5, 2.3)	2.4 (2.1, 2.7)

Data are odds ratio (95%CI). Bold text denotes 95%CI which do not include 1.

¹ Adjusted for sex, age, BMI, ethnicity, educational attainment, smoking status and number of comorbidity groupings (except when analysing this association).

Supplementary Table 1

Comorbidity groupings.

Comorbidity grouping [†]	Conditions included
1. Painful conditions	Back pain Joint pain Headaches (not migraine) Sciatica Plantar fasciitis Carpal tunnel syndrome Fibromyalgia Arthritis Shingles Disc problem Prolapsed disc/slipped disc Spine arthritis/spondylitis Ankylosing spondylitis Back problem Osteoarthritis Gout Cervical spondylosis Trigeminal neuralgia Disc degeneration Trapped nerve/compressed nerve
2. Hypertension	Hypertension Essential hypertension
3. Depression	Depression Postnatal depression
4. Asthma	Asthma
5. Coronary Heart Disease	Heart attack/MI Angina
6. Treated dyspepsia	Gastro-oesophageal reflux (GORD)/gastric reflux Oesophagitis /Barrett's oesophagus Gastric stomach ulcers Gastric erosions/gastritis Duodenal ulcer Dyspepsia/indigestion Hiatus hernia Helicobacter pylori
7. Diabetes	Diabetic nephropathy Diabetic neuropathy/ulcers Diabetes Type 1 diabetes Type 2 diabetes Diabetic eye disease
8. Thyroid disorders	Thyroid problem (not cancer) Hyperthyroidism/thyrotoxicosis Hypothyroidism/myxoedema Graves' disease Thyroid goitre Thyroiditis
9. Rheumatoid arthritis, other inflammatory polyarthropathies, systemic connective tissue disorders and systemic autoimmune disorders	Myositis/myopathy Systemic Lupus Erythematosus Connective tissue disorder Sjogren's syndrome/sicca syndrome Dermatopolymyositis Scleroderma/systemic sclerosis Rheumatoid arthritis Psoriatic arthropathy Dermatomyositis Polymyositis Polymyalgia Rheumatica Malabsorption/coeliac disease
10. Chronic Obstructive Pulmonary Disease (COPD)	COPD/chronic obstructive airways disease Emphysema/chronic bronchitis Emphysema
11. Anxiety, other neurotic, stress related and somatoform disorders	Anxiety/panic attacks Nervous breakdown Post-traumatic stress disorder Obsessive compulsive disorder

	Stress
	Insomnia
	Psychological/psychiatric problem
12. Irritable bowel syndrome	Irritable bowel syndrome
13. Alcohol problems	Alcohol dependency Alcoholic liver disease/alcoholic cirrhosis
14. Other psychoactive substance abuse	Opioid dependency Other substance abuse/dependency
15. Treated constipation	Constipation
16. Stroke and Transient Ischaemic Attack (TIA)	Stroke TIA Subarachnoid haemorrhage Brain haemorrhage Ischaemic stroke
17. Chronic kidney disease	Polycystic kidney Diabetic nephropathy Renal/kidney failure Renal failure requiring dialysis Renal failure not requiring dialysis Kidney nephropathy Immunoglobulin A (IgA) nephropathy
18. Diverticular disease of intestine	Diverticular disease/diverticulitis
19. Atrial fibrillation	Atrial fibrillation
20. Peripheral vascular disease	Peripheral vascular disease Leg claudication/intermittent claudication
21. Heart failure	Cardiomyopathy Hypertrophic cardiomyopathy Heart failure/pulmonary oedema
22. Prostate disorders	Prostate problem (not cancer) Enlarged prostate Benign prostatic hypertrophy
23. Glaucoma	Glaucoma
24. Epilepsy	Epilepsy
25. Dementia	Dementia/Alzheimer/cognitive impairment
26. Schizophrenia (and related non-organic psychosis) and bipolar disorder	Schizophrenia Mania/bipolar disorder/manic depression
27. Psoriasis or eczema	Eczema/dermatitis Psoriasis
28. Inflammatory bowel disease	Inflammatory bowel disease Crohn's disease Ulcerative colitis
29. Migraine	Migraine
30. Chronic sinusitis	Chronic sinusitis
31. Anorexia or bulimia	Anorexia, bulimia/other eating disorder
32. Bronchiectasis	Bronchiectasis
33. Parkinson's disease	Parkinson's disease
34. Multiple sclerosis	Multiple sclerosis
35. Viral Hepatitis	Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D Hepatitis E
36. Chronic liver disease	Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis
37. Osteoporosis	Osteoporosis
38. Chronic fatigue syndrome	Chronic fatigue syndrome
39. Endometriosis	Endometriosis
40. Meniere disease	Meniere disease
41. Pernicious Anaemia	Pernicious anaemia
42. Polycystic ovaries	Polycystic ovaries
43. Cancer	Lifetime diagnosis

¹ Self-reported lifetime diagnoses by a doctor, during face-to-face interviews at study recruitment (UK Biobank data field 20002), apart from cancer, which was reported during touchscreen questionnaires (UK Biobank data field 2453). Based on previous work by Barnett and colleagues [17] and Nicholl and colleagues [18].